Semaglutide · GLP-1 receptor agonist · research use only
Semaglutide dosage, read straight from the escalation label.
Semaglutide is a single GLP-1 receptor agonist, and its dosing is defined by a slow four-week-per-step escalation published in the STEP and SUSTAIN programmes and the FDA labels. This page lays out the once-weekly 0.25→2.4 mg ladder, the reason the maintenance ceiling differs between formulations, the ~7-day half-life that makes it the longest-acting of the common incretins, and how a mono-agonist differs from the triple agonist Titan actually stocks — framed as a research reference, not a human dosing protocol or medical advice. Titan does not sell semaglutide; the in-class compound it supplies is retatrutide.
The 0.25 → 2.4 mg escalation
The obesity label starts semaglutide at 0.25 mg once weekly for four weeks — a tolerability-initiation dose, not therapeutic — then escalates at four-week intervals: 0.5, 1.0, 1.7 and a 2.4 mg maintenance dose. The diabetes formulation uses the same 0.25 mg start but tops out lower, at a 2 mg ceiling. The gradual ramp is there to manage the GI effects common to the GLP-1 class.
Semaglutide vs retatrutide →~7-day half-life — the longest of the three
Semaglutide's half-life is reported at roughly 7 days (about 165 hours) — longer than tirzepatide's ~5 days and retatrutide's ~6 — which is why once-weekly dosing holds plasma levels steady and why a missed dose can be taken within about five days. The long clock also means steady-state is approached over roughly five weeks, matching the four-week hold between escalation steps.
Compare half-lives →Reconstitution math, in microgram territory
Semaglutide's research doses sit an order of magnitude below tirzepatide and retatrutide, so the draws are small. As a worked example, a 5 mg vial reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL, so 0.10 mL on a U-100 syringe draws 250 mcg and 0.20 mL draws 500 mcg. Because the increments are tenths of a milligram, confirm every draw against the calculator before any in-vitro work.
Run the numbers →One receptor vs three
Semaglutide acts at a single receptor, GLP-1. Retatrutide — the compound Titan stocks — engages three (GLP-1, GIP and glucagon), which is why its trial doses run to 12 mg weekly while semaglutide's obesity ceiling is 2.4 mg. If a protocol compares incretin agents, the receptor count and the two-orders-of-magnitude dose gap are the variables that separate them.
See the retatrutide vial →Confirm identity before modelling
At microgram draws, a purity or identity error is easy to miss and hard to recover from. For any GLP-1-class analog, confirm mass-spec identity and an HPLC main-peak result against a stated target before building a dosing model. Titan documents identity and purity on a lot-matched release sheet for what it stocks; hold any out-of-catalog vendor to the same standard.
How to read a COA →Research-use framing
These figures describe doses reported in human clinical trials and the FDA labels, reproduced here as a research reference for in-vitro and laboratory modelling — not as instructions for human use. Semaglutide is a prescription medicine; Titan does not sell it and supplies only research-use-only reagents, not for human or animal consumption. Nothing here is medical or dosing advice.
Research-use policy →The detail, in plain terms
The dosing reference, in one table.
Semaglutide's escalation is published in the FDA labels and the STEP/SUSTAIN trials. These are the variables a researcher weighs when modelling its titration — reproduced as a reference, not a human protocol. Titan stocks retatrutide, not semaglutide.
- Compound
- Semaglutide — single GLP-1 receptor agonist.
- Obesity-label doses
- 0.25, 0.5, 1.0, 1.7, 2.4 mg once weekly (subcutaneous).
- Titration
- Start 0.25 mg × 4 weeks, escalate every 4 weeks to a 2.4 mg ceiling (2 mg for the diabetes formulation).
- Half-life
- ≈7 days (~165 h) — longest of the common incretins; basis for weekly cadence.
- Titan catalog
- Not stocked. In-class compound Titan sells: retatrutide 10mg, $199.99 (triple agonist).
- Reconstitution
- 5 mg vial + 2 mL BAC water → 2.5 mg/mL (0.10 mL = 250 mcg).
Questions researchers ask
Before you order.
- What is the semaglutide dosing schedule used in the research?
- The obesity label starts semaglutide at 0.25 mg once weekly for four weeks, then escalates at four-week intervals through 0.5, 1.0, 1.7 and a 2.4 mg maintenance dose. The diabetes formulation uses the same start but caps at 2 mg. These figures are reproduced as a laboratory research reference; they are not a human dosing protocol or medical advice.
- Why is the semaglutide ceiling sometimes 2 mg and sometimes 2.4 mg?
- The two figures come from two formulations: the diabetes product tops out at a 2 mg weekly maintenance dose, while the obesity product escalates to 2.4 mg. Both start at 0.25 mg and step up every four weeks. The distinction matters when matching a reference dose to the correct trial programme.
- What is semaglutide's half-life?
- Semaglutide's half-life is reported at roughly 7 days (about 165 hours), the longest of the common incretin agents — longer than tirzepatide's ~5 days and retatrutide's ~6. That long clock is why once-weekly dosing is standard and why steady-state is approached over roughly five weeks.
- Does Titan sell semaglutide?
- No. Titan does not stock semaglutide, which is a prescription medicine. The compound Titan supplies in the same incretin class is retatrutide, a triple GLP-1/GIP/glucagon agonist, sold strictly as a research-use-only reagent. This page is an informational dosing reference and an honest pointer to what Titan actually carries.
- Is semaglutide approved for the uses discussed here?
- Semaglutide is an approved prescription medicine, but nothing on this page is a treatment recommendation. The dosing figures are reproduced strictly as a research reference for in-vitro and laboratory modelling. Titan supplies research-use-only reagents — not for human or animal consumption, diagnosis, treatment, or prevention — and nothing here is medical or dosing advice.